New publication: Bristol-Myers Squibb study
Clinical biomarker studies are often hindered by the scarcity or suboptimal quality of biological specimens. [HTG] EdgeSeq [platform], a transcriptomics analysis platform, combines quantitative nuclease protection assay technology with next-generation sequencing, using small amounts of starting material and delivering reproducible gene expression profiles from challenging material, such as formalin-fixed, paraffin-embedded (FFPE) tissue. To evaluate [the HTG] EdgeSeq [platform] for analysis of archives of stained FFPE tissue, [the HTG] EdgeSeq [platform] was performed on unstained, hematoxylin and eosin (H&E) estained, and immunohistochemistry-stained slides from patients with small-cell and nonesmall-cell lung cancer. Pairwise comparisons of gene expression profiles from stained and unstained slides showed higher Pearson correlation coefficients with H&E staining (0.86 to 0.97) than with immunohistochemistry staining (0.21 to 0.56). Read the full publication here.